Phibro Animal Health President and CEO Sells 72k Shares After Strong Q2 2026 Performance

This animal health company recently had a strong earnings report, and shortly after, its President and CEO sold thousands of shares. Jack Bendheim, President and CEO of Phibro Animal Health Corporation (PAHC +1.83%), reported the indirect sale of 72,198 shares in multiple open-market transactions between Feb. 10 and Feb. 11, 2026, for a total value of approximately $3.74 million, according to a SEC Form 4 filing. Transaction summary MetricValueShares sold72,198Transaction value$3.7 millionPost-transaction shares (direct)16,840Post-transaction shares (indirect)50,760Post-transaction value (direct ownership)$868,000Transaction value based on SEC Form 4 weighted average purchase price ($51.77); post-transaction value based on Feb. 11, 2026 market close ($51.52). Key questionsWhat proportion of Jack Bendheim’s ownership was impacted by this transaction?Approximately 51.64% of his aggregate holdings (direct and indirect) were disposed, with the indirect account (BFI Co. LLC) experiencing a 58.72% reduction. What was the context of the sale execution? The transactions occurred under a pre-existing Rule 10b5-1 trading plan, at a weighted average price of around $51.77 per share. A 10b5-1 trading plan allows insiders to sell or buy shares at a pre-determined date. Company overview MetricValueRevenue (TTM)$1.46 billionNet income (TTM)$92.09 millionDividend yield1.88%1-year price change118.45%* 1-year price change calculated using Feb. 21, 2026 as the reference date. ExpandNASDAQ: PAHCPhibro Animal HealthToday's Change(1.83%) $0.95Current Price$52.80Key Data PointsMarket Cap$2.1BDay's Range$50.94 - $52.8052wk Range$16.16 - $56.30Volume215KAvg Vol268KGross Margin31.78%Dividend Yield0.91%Company snapshot Phibro Animal Health Corporation develops, manufactures, and supplies animal health and mineral nutrition products for livestock, serving customers in the United States and internationally. It focuses on producing antibacterials, anticoccidials, anthelmintics, nutritional specialty products, vaccines, and trace minerals for animals such as poultry, swine, and cattle producers. What this transaction means for investorsWith Bendheim’s sale of shares being pre-determined due to a 10b5-1 trading plan, the transactions weren’t involved with any recent news surrounding Phibro. The animal health company recently had its Q2 earnings report for fiscal year 2026, seeing year-over-year (YoY) growth in revenue, net income, and earnings-per-share (EPS). In its earnings call, Bendheim expressed confidence in Phibro’s future performance with its animal nutrition products and vaccines remaining a staple of its operations. The CEO also highlighted how the company’s Medicated Feed Additive (MFA) portfolio, which consists of animal feed products that help against diseases, has grown faster than expected. The portfolio grew substantially when Phibro acquired over 37 product lines of feed products in late 2024. With diseases such as bird flu still posing as a threat to farmers and animal-product providers, the range of medicated food products will remain a necessity for those entities. The company’s stock has performed strongly over the past three years and is already up approximately 41% in 2026. Stocks MentionedPhibro Animal HealthNASDAQ: PAHC$52.80 (+1.83%) $+0.95*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.